Evidence map›Paper›PMID 42724150›Full record

ReviewComprehensive physiology2026

Short-Chain Fatty Acids: Microbial Metabolites Driving Gut-Eye Axis Signaling.

Aleah J Brokemond, Ronny Amamoo, Fapianey J Alexandre, Sewedo B Ajisegiri, Menaka C Thounaojam, Pamela M Martin, Ravirajsinh N Jadeja

Abstract readReview
In one paragraph

Review in Comprehensive physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aleah J BrokemondDepartment of Biomedical Sciences, School of Graduate Studies Meharry Medical College Nashville Tennessee USA.ORCID https://orcid.org/0009-0004-3777-2175
Ronny AmamooDepartment of Biomedical Sciences, School of Graduate Studies Meharry Medical College Nashville Tennessee USA.ORCID https://orcid.org/0009-0001-3746-7021
Fapianey J AlexandreDepartment of Biomedical Sciences, School of Graduate Studies Meharry Medical College Nashville Tennessee USA.
Sewedo B AjisegiriDepartment of Biomedical Sciences, School of Graduate Studies Meharry Medical College Nashville Tennessee USA.ORCID https://orcid.org/0009-0008-0656-1649
Menaka C ThounaojamDepartment of Biomedical Sciences, School of Graduate Studies Meharry Medical College Nashville Tennessee USA.ORCID https://orcid.org/0000-0003-0408-972X
Pamela M MartinDepartment of Biomedical Sciences, School of Graduate Studies Meharry Medical College Nashville Tennessee USA.ORCID https://orcid.org/0000-0001-6278-4953
Ravirajsinh N JadejaDepartment of Biomedical Sciences, School of Graduate Studies Meharry Medical College Nashville Tennessee USA.ORCID https://orcid.org/0000-0002-1712-454X

Funding

Research Training in Cardivascular Biology at MeharryT32HL007737 · NHLBI · MEHARRY MEDICAL COLLEGE · PI MARTIN, PAMELA M · 1993 to 2025
$4.7M
MOLECULAR PARASITOLOGY TRAINING PROGRAMT32AI007281 · NIAID · MEHARRY MEDICAL COLLEGE · PI NDE, PIUS N · 1985 to 2025
$3.2M
HBI-002 to Treat Diabetic RetinopathyR44EY033264 · NEI · HILLHURST BIOPHARMACEUTICALS, INC. · PI GOMPERTS, EDWARD, JADEJA, RAVIRAJSINH · 2024 to 2025
$1.9M
The Meharry Research Training InitiativeT32GM144927 · NIGMS · MEHARRY MEDICAL COLLEGE · PI Pamela M Martin · 2022 to 2026
$1.9M
Bile acid receptor signaling in retinopathy of prematurityR01EY034568 · NEI · MEHARRY MEDICAL COLLEGE · PI Menaka Chanu Thounaojam · 2023 to 2026
$1.5M
BRE-SPAD at MeharryUC2GM162929 · NIGMS · MEHARRY MEDICAL COLLEGE · PI Amadou Gaye, MERRY L. LINDSEY · 2026 to 2026
$684k
Short-chain fatty acid signaling in retinopathy of prematurityR56EY035336 · NEI · AUGUSTA UNIVERSITY · PI JADEJA, RAVIRAJSINH · 2024 to 2024
$385k
HBI-002 to Treat Diabetic RetinopathyR41EY033264 · NEI · HILLHURST BIOPHARMACEUTICALS, INC. · PI GOMPERTS, EDWARD, JADEJA, RAVIRAJSINH · 2021 to 2021
$300k
NEI NIH HHS R01 EY034568NEI NIH HHS R41 EY033264NEI NIH HHS R44 EY033264NEI NIH HHS R56 EY035336NHLBI NIH HHS T32 HL007737NIAID NIH HHS T32 AI007281NIGMS NIH HHS T32 GM144927NIGMS NIH HHS UC2 GM162929
6 · The paper itself

Abstract

Short-chain fatty acids (SCFAs) have emerged as key molecular mediators of gut-eye communication, linking microbial metabolism to ocular physiology and disease. Produced through microbial fermentation of dietary fiber, SCFAs function as systemic signaling molecules that regulate immune homeostasis, metabolic function, vascular integrity, and neuroinflammatory pathways through activation of SCFA-responsive receptors and epigenetic mechanisms. Growing evidence indicates that SCFAs influence biological processes central to ocular health, including inflammation, oxidative stress, neurodegeneration, and pathological angiogenesis. Experimental, metabolomic, and emerging clinical studies suggest that disruptions in SCFA signaling may contribute to the pathogenesis of retinal and ocular surface diseases; however, the mechanisms governing ocular exposure, target engagement, and therapeutic efficacy remain incompletely understood, highlighting a critical gap between mechanistic insight and clinical translation. In this review, we integrate current evidence into a mechanistic and translational framework that positions SCFAs as central effectors of the gut-eye axis. We further evaluate the therapeutic potential of SCFA modulation and identify key barriers to clinical implementation, including bioavailability, pharmacokinetics, dosing, and long-term safety, thereby delineating a roadmap for the development of microbiome-derived precision therapeutics in ophthalmology.

Indexed as

butyrategut‐eye axismicrobiomeocular diseasesshort‐chain fatty acids

Identifiers

PMID42724150
PMCPMC13559049

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.